Pneumocystis in Patients Over 75 Year

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

162 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-01-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pneumocystis pneumonia is an infectious disease caused by Pneumocystis jirovecii that affects the lung parenchyma preferentially. Historically described in an immunocompromised population through HIV.

Worldwide, the profile of patients affected by this pathology is changing due to two main factors:

* The sustainable stabilization of HIV patients.
* The emergence of new risk factors of immunosuppression. The geriatric population is particularly affected by these risk factors, increasing the incidence of pneumocystis in this population, which does not have HIV (solid cancer, hemopathy, immunosuppressive treatments, etc.).

There is currently no work specifically studying pneumocystis in this age group. The main objective of this study is to describe the clinical, biological and therapeutic data of a cohort of geriatric patients with pneumocystis, not carrying HIV, from January 1, 2010 to December 31, 2021, in all the centers surveyed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients

NCT05458752

Pneumocystis Jirovecii Infection

COMPLETED

Pneumocystis Pneumonia Diagnosis in HIV- Patients

NCT02648256

Pneumonia, Pneumocystis

UNKNOWN NA

Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients

NCT02944045

Pneumocystis Steroids Immunocompromised Patient +3 more

UNKNOWN PHASE3

Caspofungin for Pneumocystis Pneumonia in PLWHIV.

NCT06691321

HIV-1-infection Pneumocystis Pneumonia

RECRUITING

Specific Genotypes/Phenotypes of Pneumocystis Jirovecii in Solid Organ Transplant Recipients: Potential Involvement of Mycophenolic Acid

NCT05452148

Transplantation Pulmonary Diseases

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumocystis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

geriatric patient with pneumocystis

geriatric patient with pneumocystis, not HIV positive,

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient \> or equal to 75 years of age
2. Microbiological diagnosis:

* Direct examination with standard stain, finding trophozoite and/or P.jirovecii cyst (BAL or induced sputum) And/or
* Direct examination with immunofluorescence, finding trophozoite and/or P.jirovecii cyst (BAL or induced sputum)
* And/or
* Positive PCR (BAL, sputum, nasopharyngeal swab or blood) and CT \< 35
3. Absence of HIV infection
4. Hospitalization in French hospitals between 2010 and 2021

1\. Opposition of the patient to participate to the study

Minimum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No